Prognostic factors for medium- and long-term survival of esophageal cancer patients in the Netherlands

Abstract Background The aim of this study was to explore the prognostic factors and establish a nomogram to predict the long-term survival of gastric cancer patients. Methods The clinicopathological data of 421 gastric cancer patients, who were treated with radical D2 lymphadenectomy by the same surgical team between January 2009 and March 2017, were collected. The analysis of long-term survival was performed using Cox regression analysis. Based on the multivariate analysis results, a prognostic nomogram was formulated to predict the 5-year survival rate probability. Results In the present study, the total overall 3-year and 5-year survival rates were 58.7 and 45.8%, respectively. The results of the univariate Cox regression analysis revealed that tumor staging, tumor location, Borrmann type, the number of lymph nodes dissected, the number of lymph node metastases, positive lymph nodes ratio, lymphocyte count, serum albumin, CEA, CA153, CA199, BMI, tumor size, nerve invasion, and vascular invasion were prognostic factors for gastric cancer (all, P < 0.05). However, merely tumor staging, tumor location, positive lymph node ratio, CA199, BMI, tumor size, nerve invasion, and vascular invasion were independent risk factors, based on the results of the multivariate Cox regression analysis (all, P < 0.05). The nomogram based on eight independent prognostic factors revealed a well-degree of differentiation with a concordance index of 0.76 (95% CI: 0.72–0.79, P < 0.001), which was better than the AJCC-7 staging system (concordance index = 0.68). Conclusion The present study established a nomogram based on eight independent prognostic factors to predict long-term survival in gastric cancer patients. The nomogram would be beneficial for more accurately predicting the prognosis of gastric cancer, and provide important basis for making individualized treatment plans following surgery.

Download Full-text

New prognostic factors associated with long-term survival in node-negative breast cancer patients

Breast Cancer ◽

10.1007/bf02966456 ◽

1999 ◽

Vol 6 (4) ◽

pp. 370-377 ◽

Cited By ~ 4

Author(s):

Takao Kato ◽

Tsunehito Kimura ◽

Nobue Takami ◽

Ryuhei Miyakawa ◽

Schinichi Tanaka ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Term Survival ◽

Node Negative ◽

Long Term Survival ◽

Factors Associated ◽

Node Negative Breast Cancer

Download Full-text

Long term survival and the prognostic factors of advanced breast cancer patients treated with adreno-oophorectomy

Breast Cancer Research and Treatment ◽

10.1007/bf00666070 ◽

1995 ◽

Vol 33 (1) ◽

pp. 47-54 ◽

Cited By ~ 2

Author(s):

Yasuo Nomura ◽

Hideya Tashiro ◽

Akihiko Osaki

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Advanced Breast Cancer ◽

Cancer Patients ◽

Advanced Breast ◽

Breast Cancer Patients ◽

Term Survival ◽

Long Term Survival

Download Full-text

Diabetes mellitus and survival of esophageal cancer patients after esophagectomy: a systematic review and meta-analysis

Diseases of the Esophagus ◽

10.1093/dote/doz098 ◽

2020 ◽

Vol 33 (2) ◽

Author(s):

Xi Zheng ◽

Xingsheng Ma ◽

Han-Yu Deng ◽

Panpan Zha ◽

Jie Zhou ◽

...

Keyword(s):

Diabetes Mellitus ◽

Esophageal Cancer ◽

Cancer Patients ◽

Meta Analysis ◽

Outcome Data ◽

Term Survival ◽

Long Term Survival ◽

Significant Difference ◽

The Impact

SUMMARY Diabetes mellitus (DM) is one of the most common comorbidities in esophageal cancer patients who undergo esophagectomy. It is well established that DM has an unfavorable impact on short-term outcomes of patients with surgically treated esophageal cancer; however, whether DM has any impact on long-term survival of these patients remains unclear. We performed the first meta-analysis to investigate the impact of DM on survival of surgically treated esophageal cancer patients. We searched the following databases systematically to retrieve relevant studies on January 2, 2019: PubMed, Embase, and Web of Science. The main outcome data consisting of 3- and 5-year overall survival (OS) rates and hazard ratios (HRs) of OS were extracted to compare survival between patients with and without DM. We finally included for meta-analysis a total of eight cohort studies involving 5,044 esophageal cancer patients who underwent esophagectomy. We found no significant difference between 3-year (risk ratio [RR] = 0.94, 95% CI: 0.73–1.21; P = 0.65) and 5-year (RR = 0.92, 95% CI: 0.80–1.08; P = 0.31) OS rates between patients with and without DM after esophagectomy. Moreover, DM was not found to be an independent predictor of OS for these patients (HR = 1.10, 95% CI: 0.65–1.84; P = 0.72). Our study suggests that DM appears to have no significant impact on long-term survival of esophageal cancer patients who undergo esophagectomy. To improve the prognosis of these patients, it may be more important to control glycemic level in patients with DM who undergo esophagectomy. However, further high-quality studies with appropriate adjustment for confounding factors are needed to verify this conclusion.

Download Full-text

Prognostic factors and long-term survival in renal cell cancer patients

Scandinavian Journal of Urology and Nephrology ◽

10.1080/00365590903286697 ◽

2009 ◽

pp. 1-7

Author(s):

Kaisa Sunela ◽

Matti Kataja ◽

Eero Lehtinen ◽

Tapio Salminen ◽

Paula Kujala ◽

...

Keyword(s):

Prognostic Factors ◽

Cancer Patients ◽

Renal Cell Cancer ◽

Renal Cell ◽

Cell Cancer ◽

Term Survival ◽

Long Term Survival

Download Full-text

Long-term survival of women with breast cancer with ≥10 lymph nodes at diagnosis.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e11575 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e11575-e11575

Author(s):

Ludimila Cavalcante ◽

Simon B. Zeichner ◽

Gabriel P Suciu ◽

Ana L. Ruiz ◽

Alicia Hirzel ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Lymph Nodes ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Term Survival ◽

Long Term Survival ◽

Metastatic Lymph Nodes ◽

Metastatic Lymph

e11575 Background: Axillary lymph node status is one of the most important prognostic factors in patients with breast cancer, and those with more than ten metastatic lymph nodes at diagnosis have a decreased overall survival. The purpose of this study is to better characterize the clinical course of this high-risk, poorly described patient population and determine the factors associated with long-term survival. Methods: A retrospective cohort analysis of all breast cancer patients with greater than ten metastatic lymph nodes diagnosed at Mt. Sinai Medical Center from January 1990 to December 2007 (n= 175). Descriptive frequencies, overall median survival (OMS), 5- and 10-year survival were calculated for standard prognostic factors and treatment variables. Univariate statistical analysis was performed, followed by a multivariate prognostic analysis for time-to-event data, using the Cox and extended Cox regression model. Results: The majority of patients were non-Hispanic white females between the ages of 56-70, diagnosed between 1990-1999, with tumors between 2-5 cm and 10-15 metastatic lymph nodes. Most were ER/PR positive, HER2 negative, and treated with surgery, chemotherapy, radiation and hormonal therapy. The OMS was 94 months (CI = 69-114) with 5- and 10-year survival rates of 64.3 and 41.6%, respectively. Ages between 21-45 years (OMS of 187 months, p = 0.03), tumors less than 2 cm (146 months (95% CI = 85-198), p = 0.02), ER positivity (131 months (95% CI = 94-157) vs. 39 months (95% CI = 27-59), p = 0.0003) and treatment received between 2000-2003 (98 months (95% CI = 55-133), p = 0.02) were all associated with significantly improved survival. Conclusions: Over the past decade there were significant gains in the long-term survival of breast cancer patients with greater than ten positive nodes at diagnosis, possibly due to improvements in multimodality therapy, such as the introduction of taxanes, although stage migration may be another contributing factor. Our study further showed an encouraging survival for ER positive patients and a dismal one for ER negative patients, highlighting the need for new targeted therapies directed towards ER negative tumors.

Download Full-text